Registry of Lobbyists
Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Environment, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Activities related to the Convention on Biological Diversity (CBD) including Digital Sequence Information (DSI) and an Access and Benefit Sharing (ABS) framework.
|
Policies or Program
|
|
Federal-Provincial Relations, Foreign Affairs, Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
|
Legislative Proposal, Bill or Resolution
|
|
Foreign Affairs, Health, Infrastructure, Internal Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
|
Policies or Program
|
|
Economic Development, Government Procurement, Health, International Development, International Relations, International Trade, Regional Development, Research and Development
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
|
Health, Intellectual Property, International Relations, International Trade
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
|
Environment, Health, Science and Technology
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Regulation, Legislative Proposal, Bill or Resolution
|
|
Economic Development, Health, Intellectual Property, Research and Development, Science and Technology
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
|
Consumer Issues, Federal-Provincial Relations, Intellectual Property, Science and Technology
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
|
Federal-Provincial Relations, Health, Intellectual Property, Science and Technology
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
|
Consumer Issues, Health, Intellectual Property, Research and Development
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Health, Intellectual Property, International Relations, International Trade, Taxation and Finance
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution, Regulation
|
|
Health, Intellectual Property, International Relations, International Trade, Taxation and Finance
|
Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Policies or Program
|
|
Consumer Issues, Health, Industry, Intellectual Property, Research and Development
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
|
Health, Intellectual Property, International Trade, Research and Development, Science and Technology, Taxation and Finance
|
Income Tax Act as it relates to biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property, Research and Development, Science and Technology, Small Business, Taxation and Finance
|
National Strategy for Drugs for Rare Diseases
|
Policies or Program, Regulation
|
|
Health, Industry, Intellectual Property, International Trade, Research and Development, Taxation and Finance
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Intellectual Property, Research and Development, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
|
Health, Intellectual Property, International Development, International Relations, International Trade, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade, Natural Resources
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Consumer Issues, Health, Industry, Intellectual Property, International Development, International Relations, International Trade, Taxation and Finance
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
|
Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Government Procurement, Health, Industry
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
|
Economic Development, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
|
Health, Industry, Intellectual Property, Natural Resources, Science and Technology
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Policies or Program
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Address:
55 Metcalfe St.
Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Bettina Hamelin, President
Innovative Medicines Canada / Médicaments novateurs Canada is not a subsidiary of any other parent companies.
Innovative Medicines Canada / Médicaments novateurs Canada is not a coalition.
The activities of Innovative Medicines Canada / Médicaments novateurs Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Innovative Medicines Canada / Médicaments novateurs Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
BRAD LAVIGNE | No public offices held
Firm: Counsel Public Affairs Inc.